CD274 and non-small cell lung carcinoma: Not surprisingly, checkpoint inhibitors such as Pembrolizumab (Keytruda), Nivolumab (Opdivo), Ipilimumab (Yervoy), Duryalumab (Imfinzi), Cemiplimab (Libtayo), and Atezolizumab (Tecentriq) are widely used as first-line therapy against non-small-cell lung cancer (NSCLC) based on the programmed death-ligand 1 (PD-L1) status of the tumors [12,13].